Last year saw a wonderful wave of venture cash crashing into biotech coffers. The 2009 yearend numbers were up significantly from 2008, with more deals done (57 vs. 43) and investors shoveling 38 percent more into Series A, plus 36 percent more into Series B rounds. (BioWorld Today)
